Koyfin Home > Directory > Health Care > Revance Therapeutics > Issuance of Common Stock

Revance Therapeutics Issuance of Common Stock Chart (RVNC)

Revance Therapeutics annual/quarterly Issuance of Common Stock from 2012 to 2020.
  • Revance Therapeutics Issuance of Common Stock for the quarter ending June 06, 2020 was $1m a 100.00% increase of 1m year over year
  • Revance Therapeutics Issuance of Common Stock for the last 12 months ending June 06, 2020 was $132m a 17.67% increase of 23m year over year
  • Revance Therapeutics Annual Issuance of Common Stock for 2019 was $224m a 97.64% increase of 218m from 2018
  • Revance Therapeutics Annual Issuance of Common Stock for 2018 was $5m a -3,694.35% decrease of -196m from 2017
  • Revance Therapeutics Annual Issuance of Common Stock for 2017 was $201m a 99.18% increase of 199m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Issuance of Common Stock Data

06/2020$1m
03/2020$16m
12/2019$115m
09/2019$0m
06/2019$0m
03/2019$108m
12/2018$0m
09/2018$1m
06/2018$3m
03/2018$1m

Annual RVNC Issuance of Common Stock Data

2019$224m
2018$5m
2017$201m
2016$2m
2015$139m
2014$236m
2013$0m
2012$0m